
- GSK will continue to purchase the adjuvant QS-21 Stimulon® from Antigenics until 2014,
- Antigenics will transfer manufacturing technology licenses for QS-21 to GSK
- GSK will pay milestone fees and royalties for a period of at least 10 years after first commercial sale
No financial details of the deal were disclosed. A replay of conference call webcast discussing the deal may be accessed here.
More details from Antigenics' press release.






Comment Preview